Drug Profile
VX 10217
Alternative Names: VX-10217Latest Information Update: 12 May 2011
Price :
$50
*
At a glance
- Originator Vertex Pharmaceuticals
- Class Antivirals
- Mechanism of Action HIV protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV-1 infections
Most Recent Events
- 12 May 2011 Discontinued - Preclinical for HIV-1 infections in USA (unspecified route)
- 02 Sep 1998 No-Development-Reported for HIV-1 infections in USA (Unknown route)
- 08 May 1995 Preclinical development for HIV-1 infections in USA (Unknown route)